Orchard Therapeutics plc
ORTX · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $7 | $0 | $3 | $3 |
| % Growth | 1,346.4% | -81.4% | 3.3% | – |
| Cost of Goods Sold | $2 | $0 | $1 | $1 |
| Gross Profit | $5 | $0 | $2 | $2 |
| % Margin | 65.2% | 53.2% | 67% | 68% |
| R&D Expenses | $26 | $23 | $94 | $117 |
| G&A Expenses | $45 | $50 | $57 | $49 |
| SG&A Expenses | $11 | $14 | $65 | $57 |
| Sales & Mktg Exp. | $4 | $5 | $8 | $8 |
| Other Operating Expenses | $0 | $0 | $0 | $1 |
| Operating Expenses | $36 | $37 | $159 | $175 |
| Operating Income | -$32 | -$36 | -$157 | -$173 |
| % Margin | -452.2% | -7,539.3% | -6,049.2% | -6,879.1% |
| Other Income/Exp. Net | -$26 | -$3 | $4 | $7 |
| Pre-Tax Income | -$9 | -$36 | -$153 | -$166 |
| Tax Expense | -$1 | $0 | -$1 | -$2 |
| Net Income | -$8 | -$36 | -$152 | -$163 |
| % Margin | -112.8% | -7,525.7% | -5,856.6% | -6,503.1% |
| EPS | -0.61 | -2.93 | -15.28 | -17.53 |
| % Growth | 79.2% | 80.8% | 12.8% | – |
| EPS Diluted | -0.61 | -2.93 | -15.28 | -17.53 |
| Weighted Avg Shares Out | 13 | 12 | 10 | 9 |
| Weighted Avg Shares Out Dil | 13 | 12 | 10 | 9 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $0 | $3 | $7 |
| Interest Expense | $1 | $1 | $2 | $2 |
| Depreciation & Amortization | $24 | $1 | $9 | $9 |
| EBITDA | -$8 | -$36 | -$148 | -$155 |
| % Margin | -115.6% | -7,358.4% | -5,717.8% | -6,182.8% |